Israeli health-technology company QuantiHealth has raised $45 million in a funding round aimed at expanding its artificial intelligence platform, which simulates clinical trials to help pharmaceutical and biotechnology companies accelerate drug development and reduce the enormous costs associated with bringing new therapies to market. The raise marks one of the more significant venture investments in Israeli digital health infrastructure this year, reflecting sustained investor appetite for technologies that target inefficiencies deep within the drug development pipeline. It follows a broader pattern of capital flowing into Israeli technology ventures, as seen in Oligo Security’s recent $60 million raise to address cloud application vulnerabilities.
According to a report by Globes, the Israeli financial news outlet that first covered the story under the headline detailing the funding round, QuantiHealth’s platform uses large-scale real-world data and machine learning models to construct synthetic patient populations and simulate how those populations would respond to experimental treatments across trial phases. The technology is designed to serve as a complement or partial substitute for conventional trial arms, potentially compressing development timelines that can otherwise span a decade or longer.
What QuantiHealth’s Platform Actually Does
Clinical trials remain one of the most capital-intensive stages of pharmaceutical development. Industry estimates have long placed the average cost of bringing a single drug to approval north of $1 billion when accounting for failed candidates, with late-stage Phase III trials alone capable of running hundreds of millions of dollars and requiring thousands of enrolled patients over multiple years. Delays, patient recruitment failures, and protocol amendments are among the leading causes of cost overruns.
QuantiHealth addresses this by generating what it terms digital or synthetic patient cohorts — computational representations built from anonymized real-world health data — that can be used to model trial outcomes before or alongside traditional enrollment. The company’s models are intended to help sponsors identify optimal patient subgroups, predict adverse event profiles, and stress-test trial designs at a fraction of the cost of running a conventional parallel arm. Regulatory agencies in the United States and Europe have increasingly signaled openness to the use of synthetic control arms and in-silico trial components, providing a clearer pathway for companies like QuantiHealth to commercialize this approach.
Investor Composition and Commercial Strategy
The company has not disclosed the full breakdown of investors participating in the $45 million round, though the scale of the raise suggests involvement from institutional life sciences or growth-stage venture funds with experience in health-technology software. QuantiHealth intends to deploy the capital across three primary areas: expanding its underlying data infrastructure, deepening regulatory engagement with agencies such as the U.S. Food and Drug Administration, and scaling its commercial operations to sign additional pharmaceutical and biotech clients globally.
The commercial model is understood to be software-as-a-service in structure, with contract values tied to the complexity and scale of the trials being simulated. Enterprise deals with large pharmaceutical sponsors represent the primary revenue opportunity, though mid-size biotechs conducting targeted oncology or rare disease programs are also a natural customer segment given the outsized burden that trial costs place on smaller organizations with limited balance sheets. The Israel-based company is competing in a market that has attracted growing attention from a range of computational biology and AI-for-drug-discovery firms globally, making the depth of its proprietary data sets and the credibility of its simulation outputs critical competitive differentiators.
Israel’s broader digital health sector has continued to attract capital despite a challenging global venture environment, benefiting from a deep talent pool in software engineering, data science, and medical research, as well as proximity to a healthcare system that has historically supported large-scale digital health data collection. The country’s technology sector has demonstrated resilience across multiple verticals, a trend also evident in the aerospace and industrial manufacturing space, where companies such as those covered in Technologies’ record results have reported sustained demand growth. For QuantiHealth, the $45 million raise provides the operational runway to pursue regulatory validation and client expansion at a moment when the pharmaceutical industry’s appetite for cost-reduction tools remains acute.